Drug intelligence / Profile preview

Trivax

Development stage: Phase 2
Lead developer: AOP Health
Modality: Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
Administration: Intranodal

Overview

Trivax is an anti-tumor immune therapy developed by Activartis Biotech. It is based on tumor-lysate charged dendritic cells, designed to stimulate the patient's immune system to recognize and attack cancer cells. It is currently being investigated as an add-on treatment for Glioblastoma Multiforme, in combination with standard therapy including Temozolomide and radiotherapy.

Beyond the preview

Go deeper on Trivax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trivax.

Explore the full profile